STOCK TITAN

Elanco Animal Health Incorporated - ELAN STOCK NEWS

Welcome to our dedicated page for Elanco Animal Health Incorporated news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health Incorporated stock.

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health, committed to innovating and delivering products and services to improve the health and wellness of both farm animals and pets. Established with nearly 70 years of heritage, Elanco operates in over 90 countries with a diverse portfolio of approximately 200 brands. Their core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue through three primary avenues:

  • Enhancing food security by improving the health and productivity of farm animals, thereby contributing to a safer, more affordable, and abundant food supply.
  • Helping pets live longer, healthier lives through advanced veterinary products.
  • Improving food safety standards globally.

Elanco’s dedication to animal health is reflected in their continuous innovation and quality systems, driven by a shared vision of enhancing life for animals and humans alike. This commitment is evident in their recent achievements and ongoing projects. For instance, Elanco's collaboration with Agtech company, Cattler, aims to provide data-driven solutions to cattle farmers, enhancing operational efficiency and productivity through services like Benchmark™ and Experior™.

Elanco's financial health is strong, with the company reporting consistent revenue growth and strategic investments aimed at future expansion. In their recent financial results, Elanco posted a 5% growth in the fourth quarter and strengthened their commercial infrastructure to support ongoing and future growth. They also announced the divestiture of their aqua business to streamline operations and focus on core areas, which is expected to reduce their debt leverage significantly by year-end.

Environmental sustainability is another critical focus for Elanco. Their recent partnership with Athian to create a livestock carbon insetting marketplace is a significant step towards reducing greenhouse gas emissions in the dairy and beef industries. Products like Bovaer®, which significantly reduce methane emissions from cattle, exemplify Elanco's commitment to sustainable farming practices.

Overall, Elanco continues to be at the forefront of animal health innovation, with substantial investments in R&D, strategic partnerships, and a clear commitment to sustainability and community health.

Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) has joined the Greener Cattle Initiative, committing approximately $5 million over five years to fund research aimed at reducing methane emissions in beef and dairy production. This effort, led by the Foundation for Food & Agriculture Research, responds to the urgent need for climate action as highlighted by the UN. Elanco's participation aligns with its sustainability goals, including its pledge to remove 21 million tons of emissions from customer farms by 2030.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
-
Rhea-AI Summary

Elanco Animal Health reported a 27% increase in third quarter revenue, reaching $1,131 million, boosted by the Bayer Animal Health acquisition. The company updated its full-year revenue guidance to $4,730 to $4,770 million while maintaining adjusted EPS guidance of $0.97 to $1.03. However, reported EPS was $(0.21). Gross margin improved significantly to 55.6%. Elanco's operational performance reflected strong fundamentals, particularly in the Farm Animal and Pet Health sectors, with significant product contributions. The company anticipates continued growth in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.71%
Tags
none
-
Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) has been recognized in FORTUNE’s 2021 Change the World list, ranking 19th among 53 companies making a social or environmental impact. This accolade highlights Elanco's East Africa Growth Accelerator (EAGA), which supports smallholder farmers in Tanzania, Kenya, and Uganda by providing affordable veterinary products and training. The initiative, begun in 2017 with backing from the Bill & Melinda Gates Foundation, integrates into Elanco's operations, emphasizing animal health's role in addressing hunger and climate challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
none
Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) is set to announce its third quarter 2021 financial results on November 5, 2021. A conference call will follow at 8:00 a.m. eastern time to discuss the company's performance, accessible via a live webcast on Elanco's website. The company specializes in products and services aimed at preventing and treating diseases in farm animals and pets, emphasizing sustainability and community impact. With nearly 70 years of experience in animal health, Elanco aims to improve the welfare of animals globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
-
Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) announces the appointment of Ellen de Brabander, Ph.D., as the new executive vice president of Innovation and Regulatory Affairs, effective October 18. She brings extensive experience, including leading the development of NexGard. The company maintains its innovation revenue expectations of $600 to $700 million by 2025, driven by the acquisition of KindredBio and ongoing pipeline advancements. Additionally, Aaron Schacht will lead the carve-out of Elanco's microbiome R&D platform to establish an independent biopharmaceutical entity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
-
Rhea-AI Summary

Elanco Animal Health has completed the acquisition of Kindred Biosciences for $444 million, enhancing its position in the dermatology market. This acquisition is expected to bring three potential blockbusters by 2025 and add $100 million to Elanco's innovation revenue, totaling $600-$700 million. The partnership is poised to boost Elanco's annual revenue growth by 1% starting in 2024 and improve gross margins. This strategic move strengthens Elanco's commitment to addressing unmet medical needs for pets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
Rhea-AI Summary

Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021. CEO Jeff Simmons will join a virtual fireside chat at 3:30 p.m. ET. Investors can access a live audio webcast on Elanco's investor website, with a replay available for 90 days.

Elanco is a leader in animal health, focusing on innovative solutions for the well-being of farm animals and pets. With nearly 70 years of experience, they aim to enhance animal health and contribute positively to communities worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
conferences

FAQ

What is the current stock price of Elanco Animal Health Incorporated (ELAN)?

The current stock price of Elanco Animal Health Incorporated (ELAN) is $11.88 as of December 24, 2024.

What is the market cap of Elanco Animal Health Incorporated (ELAN)?

The market cap of Elanco Animal Health Incorporated (ELAN) is approximately 5.9B.

What is Elanco Animal Health's core mission?

Elanco's core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue by enhancing food security, improving pet health, and elevating food safety standards globally.

In how many countries does Elanco operate?

Elanco operates in over 90 countries worldwide.

What recent collaborations has Elanco engaged in?

Elanco recently collaborated with Agtech company Cattler to provide data-driven solutions to cattle farmers through services like Benchmark™ and Experior™.

What is the significance of Elanco's partnership with Athian?

The partnership with Athian aims to create a livestock carbon insetting marketplace, reducing greenhouse gas emissions and promoting sustainable farming practices.

What are some of Elanco's notable products?

Elanco's notable products include Seresto®, Experior™, and Bovaer®, the latter being a methane-reducing feed ingredient for cattle.

How is Elanco addressing sustainability in animal farming?

Elanco addresses sustainability through innovative products like Bovaer®, which reduces methane emissions from cattle, and partnerships aimed at creating carbon insetting marketplaces.

What financial goals has Elanco set for 2024?

Elanco expects constant currency revenue growth of 2% to 3% for 2024, driven by new product launches and operational improvements. They also anticipate significant debt reduction through strategic divestitures.

How does Elanco contribute to food safety?

Elanco contributes to food safety by developing products that improve the health and performance of farm animals, thereby ensuring a safer and more reliable food supply.

What is Elanco's approach to innovation?

Elanco's approach to innovation involves continuous R&D investments, strategic partnerships, and the development of new products that address pressing issues in animal health and sustainability.

How does Elanco support the health and wellness of pets?

Elanco supports pet health through an extensive range of veterinary products designed to improve the quality and longevity of pets' lives.

Elanco Animal Health Incorporated

NYSE:ELAN

ELAN Rankings

ELAN Stock Data

5.87B
490.44M
0.71%
98.94%
3.07%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
GREENFIELD